Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Cancer Immunology, Immunotherapy : CII|June 1, 2011
Targeting the extrinsic apoptosis signaling pathway for cancer therapyThomas J SayersCancer Immunology, Immunotherapy : CII|December 23, 2004
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosisAlan D Brooks, Thomas J SayersCancer Immunology, Immunotherapy : CII|May 3, 2005
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapyThomas J Sayers, William J MurphyCancer Immunology, Immunotherapy : CII|June 12, 2016
Using natural products to promote caspase-8-dependent cancer cell deathPoonam Tewary, A A Leslie Gunatilaka, Thomas J SayersCancer Immunology, Immunotherapy : CII|March 10, 2010
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumorsSujin Lee, Hideo Yagita, Thomas J Sayers, et al.Expert Review of Vaccines|June 4, 2010
New flow cytometric assays for monitoring cell-mediated cytotoxicityLiubov Zaritskaya, Michael R Shurin, Thomas J Sayers, et al.Plos One|August 12, 2014
Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cellsKevin T Sayers, Alan D Brooks, Thomas J Sayers, et al.Immunology and Cell Biology|January 13, 2006
TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancerErika Cretney, Anil Shanker, Hideo Yagita, et al.Molecular Cancer Research : MCR|May 6, 2010
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complexAlan D Brooks, Kristen M Jacobsen, Wenqing Li, et al.Cells|April 9, 2014
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical TrialsAnatoli M Malyguine, Susan Strobl, Kimberly Dunham, et al.Pageof 5